A5067922610- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
- Breast Cancer Treatment Studies
- Cancer Genomics and Diagnostics
- Pelvic floor disorders treatments
- HER2/EGFR in Cancer Research
- Colorectal Cancer Treatments and Studies
- Sarcoma Diagnosis and Treatment
- Immunotherapy and Immune Responses
- Gastrointestinal Tumor Research and Treatment
- Intellectual Property Rights and Media
- Metastasis and carcinoma case studies
- Pancreatic and Hepatic Oncology Research
- Neuroblastoma Research and Treatments
- Polish Legal and Social Issues
- Prostate Cancer Diagnosis and Treatment
- Neuroendocrine Tumor Research Advances
- Radiomics and Machine Learning in Medical Imaging
- Testicular diseases and treatments
- Urinary Bladder and Prostate Research
- Biosimilars and Bioanalytical Methods
- Breast Lesions and Carcinomas
Andrzej Frycz Modrzewski Krakow University
2023-2024
Centrum Onkologii
2013-2016
The Maria Sklodowska-Curie National Research Institute of Oncology
2011-2016
Cancer continues to be the leading cause of mortality in high-income countries, necessitating development more precise and effective treatment modalities. Immunotherapy, specifically adoptive cell transfer T receptor (TCR)-engineered cells (TCR-T therapy), has shown promise engaging immune system for cancer treatment. One biggest challenges TCR-T therapies is proper prediction pairing between TCRs peptide-human leukocyte antigen (pHLAs). Modern computational immunology, using artificial...
BACKGROUND Radiotherapy is explicitly indicated as one of the excluding factors in diagnosing overactive bladder syndrome (OAB). Nevertheless, symptoms OAB such urgent episodes, incontinence, pollakiuria, and nocturia, which are consequences irradiation, led us to test effectiveness VESIcare®/Solifenacin patients demonstrating these after radiation therapy small pelvis organs due malignant neoplasm. MATERIAL AND METHODS We conducted an observatory clinical study including 300 consecutive...
Developing innovative precision and personalized cancer therapeutics is essential to enhance survivability, particularly for prevalent types such as colorectal cancer. This study aims demonstrate various approaches discovering new targets therapies using artificial intelligence (AI) on a Polish cohort of patients.
ENWEndNote BIBJabRef, Mendeley RISPapers, Reference Manager, RefWorks, Zotero AMA Jaszczyński J, Wilk W, Kruczak A, et al. Histopathological assessment of residual retroperitoneal mass removed in patients after chemotherapy for non-seminomatous germ cell tumours the testis. Polish Journal Pathology. 2015;66(4):420-425. doi:10.5114/pjp.2015.57257. APA Jaszczyński, J., Wilk, W., Kruczak, A., Wohadlo, Ł., Faron, P., & Łuczyńska, E. (2015). Pathology, 66(4), 420-425....
Introduction . Infiltrating lobular breast cancer (ILC) accounts for approximately 5–10% of all types. The purpose this study is to present the clinico-pathological characteristics and treatment results in patients treated classical variant ILC (C-ILC). Material methods analysis was performed group 220 with C-ILC between 1980 2005. Stage I or II found 67.7% patients, 172 (78.2%) tumour diameter lower than 5 cm (78.2%), 121 (55%) did not develop lymph node metastases. Immunohistochemical...
Poprawa ochrony zdrowia w ostatnich dekadach powoduje wydłużenie życia i starzenie się społeczeństwa, jednak pociąga za sobą rosnące koszty leczenia. Częstość oznaczania poziomu PSA wpływa na wzrost wskaźnika wykrywalności zachorowań raka stercza (RS). Był on drugim co do częstości szóstą przyczyną zgonów z powodu nowotworów złośliwych świecie 2008 roku. Przed wprowadzeniem dominowały rozpoznania zaawansowanych przypadków RS. W USA 1988 roku RS miejscowo zaawansowanego (T3-4) rozpoznano u...
<sec> <title>BACKGROUND</title> Cancer continues to be the leading cause of mortality in high-income countries, necessitating development more precise and effective treatment modalities. Immunotherapy, specifically adoptive cell transfer T receptor (TCR)-engineered cells (TCR-T therapy), has shown promise engaging immune system for cancer treatment. One biggest challenges TCR-T therapies is proper prediction pairing between TCRs peptide-human leukocyte antigen (pHLAs). Modern computational...